StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners decreased their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 1.3 %

Shares of Aspira Women’s Health stock opened at $0.75 on Wednesday. Aspira Women’s Health has a 52 week low of $0.72 and a 52 week high of $5.65. The company has a market capitalization of $12.04 million, a PE ratio of -0.52 and a beta of 1.44. The stock’s fifty day moving average is $0.85 and its two-hundred day moving average is $1.41.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.